Timber's TMB-001 receives orphan drug designation from EC to treat XLRI
Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI).
Page 2 - John Koconis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from John Koconis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In John Koconis Today - Breaking & Trending Today
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
24.02.2023 - Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) - via NewMediaWire – Timber Pharmaceuticals, Inc. ('Timber' or the “Company”) ... Seite 1
Source: wallstreet-online.de
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
14.09.2022 - European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING RIDGE, NJ, Sept. 14, 2022 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. ('Timber' or the “Company”) (NYSE ... Seite 1
Source: wallstreet-online.de
Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Source: apnews.com
Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study
- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements...
Source: globenewswire.com